Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The Golubic et al.31 trial was not included in the meta-analysis of trials in CRC patients due to a high risk of bias, see below.Characteristics of included trials.Name (country, year)Rx durationTotal/CRC casesaParticipant populationInterventionComparatorPrimary outcomeRelevant secondary outcomeFollow-up from Rx startCRC deathsOverall survivalCRC-specific survivalProgression-free survivalCRC/adenoma trials Golubic et al.31 (Croatia, 2018)2 years71/71Metastatic CRC, age 24 to 79 years2000 IU/day vitamin D3 + standard chemotherapyNo placeboOSPFS46 monthsNot knownHR = 1.01 (95% CI 0.39 to 2.61)NAHR = 1.11 (95% CI 0.69 to 1.77) SUNSHINE32 (USA, 2019)23 months139/139Metastatic CRC4000 IU/day vitamin D3 + standard chemotherapy400 IU/day vitamin D3PFSOS23 months11124.3 vs. 24.3 months; P = 0.43NAHR = 0.64 (95% CI 0 to 0.90) AMATERASU33 (Japan, 2019)3.5 years201/201Epithelial carcinoma of digestive tract (stages 1 to 3)2000 IU/day vitamin D3 + standard chemotherapyPlaceboPFSOS3.5 yearsNot knownHR = 0.95 (95% CI 0.57 to 1.57)NAHR = 0.69 (95% CI 0.39 to 1.24)Population trials Trivedi et al.34 (UK, 2003)5 years2686/55Aged 65 to 85 years100,000 IU/4m vitamin D3PlaceboFracture incidence, mortalityColon-DSSNA18NAHR = 0.62 (95% CI 0.24 to 1.60)NA WHI trial7 (USA, 2006)7 years36,282/322Post-menopausal women, 50 to 79 years400 IU/day vitamin D3 + CaCO3PlaceboHip fractureCRC risk7 years75HR = 0.91 (95% CI 0.83 to 1.01); (total trial mortality)HR0.82 (95% CI 0.52 to 1.29)NA RECORD trial39 (UK, 2012)24 to 62 months5292/71Aged >70 years, fracture800 IU/day vitamin D3 ± calciumPlacebo ± calciumFractureOS, PFS24: 62 months33HR = 0.80 (95% CI 0.61 to 1.11) (total trial mortality)20/41 deaths (vitamin D3) vs.13/30; P = 0.83†NA VITAL trial35 (USA, 2019)5 years25,871/98Men ≥50 years, women ≥55 years2000 IU/day vitamin D3 + omega-3 fatty acidsPlaceboInvasive cancer riskCancer mortality5.3 years25NAHR = 0.65 (95% CI 0.28 to 1.50)HR = 0.79 (95% CI 0.36 to 1.75)Rx intervention/comparator duration, IU International units, 4m every 4 months, CaCO3 calcium carbonate, OS overall survival, PFS progression-free survival, DSS disease (CRC)-specific survival, colon-DSS colon cancer disease-specific survival, HR hazard ratio with 95% CI given within parentheses, NA not available.aCRC number given as recruited cases or incident cases.†P value was not reported in this paper; χ2 test was performed here.
Source: Literature search. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials
Source: Article title.
The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials
Systematic review · British Journal of Cancer · 2020
Original publication title
The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials
© The Author(s) 2020
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Low circulating vitamin D levels are associated with poor colorectal cancer (CRC) survival. We assess whether vitamin D supplementation improves CRC survival outcomes.
Source: BackgroundAbstract: What methods does the paper describe?
PubMed and Web of Science were searched. Randomised controlled trial (RCTs) of vitamin D supplementation reporting CRC mortality were included. RCTs with high risk of bias were excluded from analysis. Random-effects meta-analysis models calculated estimates of survival benefit with supplementation. The review is registered on PROSPERO, registration number: CRD42020173397.
Source: MethodsAbstract: Results
Seven RCTs (n = 957 CRC cases) were identified: three trials included patients with CRC at outset, and four population trials reported survival in incident cases. Two RCTs were excluded from meta-analysis (high risk of bias; no hazard ratio (HR)). While trials varied in inclusion criteria, intervention dose and outcomes, meta-analysis found a 30% reduction in adverse CRC outcomes with supplementation (n = 815, HR = 0.70; 95% confidence interval (CI): 0.48 to 0.93). A beneficial effect was seen in trials of CRC patients (progression-free survival, HR = 0.65; 95% CI: 0.36 to 0.94), with suggestive effect in incident CRC cases from population trials (CRC-specific survival, HR = 0.76; 95% CI: 0.39 to 1.13).
No heterogeneity or publication bias was noted.
Source: ResultsAbstract: Conclusions
Meta-analysis demonstrates a clinically meaningful benefit of vitamin D supplementation on CRC survival outcomes. Further well-designed, adequately powered RCTs are needed to fully evaluate benefit of supplementation in augmenting ‘real-life’ follow-up and adjuvant chemotherapy regimens, as well as determining optimal dosing.
Source: ConclusionsAuthors’ abstract
Background
Low circulating vitamin D levels are associated with poor colorectal cancer (CRC) survival. We assess whether vitamin D supplementation improves CRC survival outcomes.
Methods
PubMed and Web of Science were searched. Randomised controlled trial (RCTs) of vitamin D supplementation reporting CRC mortality were included. RCTs with high risk of bias were excluded from analysis. Random-effects meta-analysis models calculated estimates of survival benefit with supplementation. The review is registered on PROSPERO, registration number: CRD42020173397.
Results
Seven RCTs (n = 957 CRC cases) were identified: three trials included patients with CRC at outset, and four population trials reported survival in incident cases. Two RCTs were excluded from meta-analysis (high risk of bias; no hazard ratio (HR)). While trials varied in inclusion criteria, intervention dose and outcomes, meta-analysis found a 30% reduction in adverse CRC outcomes with supplementation (n = 815, HR = 0.70; 95% confidence interval (CI): 0.48 to 0.93). A beneficial effect was seen in trials of CRC patients (progression-free survival, HR = 0.65; 95% CI: 0.36 to 0.94), with suggestive effect in incident CRC cases from population trials (CRC-specific survival, HR = 0.76; 95% CI: 0.39 to 1.13).
No heterogeneity or publication bias was noted.
Conclusions
Meta-analysis demonstrates a clinically meaningful benefit of vitamin D supplementation on CRC survival outcomes. Further well-designed, adequately powered RCTs are needed to fully evaluate benefit of supplementation in augmenting ‘real-life’ follow-up and adjuvant chemotherapy regimens, as well as determining optimal dosing.
Publication and source details
Original title: The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials
Peter G. Vaughan-Shaw; Louis F. Buijs; James P. Blackmur; Evi Theodoratou; Lina Zgaga; Farhat V. N. Din; Susan M. Farrington; Malcolm G. Dunlop
British Journal of Cancer · 2020
© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100000289Cancer Research UK (CRUK)C157/A23218Blackmur James P. ECAT-linked CRUK ECRC Clinical training award (C157/A23218)Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T02:27:20.486331+00:00
DOI: 10.1038/s41416-020-01060-8 · PMC7686489